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Disparities in receipt of 
radiotherapy and survival by age, 
sex, and ethnicity among Patient 
with stage i Follicular lymphoma
Amir Bista1 , Sandhya Sharma1 and Binay Kumar Shah2*
1 Guthrie Robert Packer Hospital, Sayre, PA, USA, 2 PeaceHealth United General Hospital, Sedro Woolley, WA, USA
Background: Radiotherapy (RT) is a first-line treatment option for stage I follicular 
lymphoma (FL). We studied disparities in receipt of RT and survival among patients with 
stage I FL.
Methods: Adult patients (age ≥18 years) with stage I FL, as the first primary cancer, 
diagnosed between 1992 and 2007 were identified using Surveillance, Epidemiology, 
and End Results (SEER) 18 database. Study population was divided into various sub-
groups based on age, sex, race, and marital status. Factors associated with receipt of 
RT and survival, among patients receiving RT, was evaluated using regression analysis 
and Cox PH modeling, respectively. SEER*Stat was used to compute 1- and 5-year RS 
for various subgroups and compared using Z score.
results: Of the total 7315 patients (median age: 64 years), 2671 (36.5%) received RT. 
African-Americans, older age group, and single and separated/divorced/widow mari-
tal status predicted omission of RT. The 1- and 5-year RS were significantly better in 
patients receiving RT. In multivariate analysis, male sex, age <60 years, Caucasian race, 
and married marital status were found to be independent predictor of better RS among 
patients receiving RT (P < 0.0001).
conclusion: This study showed that 36.5% patients with stage I FL received RT. Survival 
rates were significantly better for patients who received RT.
Keywords: follicular lymphoma, radiotherapy, survival, seer, ethnicity
inTrODUcTiOn
Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma (NHL) with inci-
dence of 3.7 per 100,000 in the United States (1). In a recent analysis of Surveillance, Epidemiology, 
and End Results (SEER) database, 26% of patients with FL had stage I disease (2). Radiation therapy 
is an effective therapy for limited stage FL and may be curative in significant proportion of the 
patients (3–5). In fact, National Comprehensive Cancer Network recommends radiotherapy (RT) as 
the preferred option. A retrospective analysis of SEER database for stage I FL diagnosed from 1973 to 
2004 showed that upfront RT significantly improved disease specific and overall survival of patients 
(6). Another population-based study showed significant improvement in survival of patients with 
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RT compared to those who did not receive RT (5- and 10-year 
OS rates of 86 and 68%, respectively, compared with 74 and 54%, 
respectively, with P < 0.0001) (7).
We conducted this population-based study to analyze factors 
associated with the receipt of RT and survival among patients 
with stage I FL.
MeThODs anD MeThODOlOgY
Surveillance, Epidemiology, and End Results 18 registry 2014 
submission was used to identify adult patients with stage I FL 
as first primary. SEER database is the National Cancer Institute 
sponsored population-based database that collects incidence and 
survival data on cancer cases from various locations and sources 
in the United States. SEER 18 covers about 27.8% of total US 
population (8). SEER program maintains high case ascertain-
ment of about 98% by conducting rigorous quality control studies 
every other year (9).
Lymphoma subtype recode/WHO 2008 was used to identify 
patients with FL and AJCC lymphoma Ann Arbor Stage (1983+) 
was used to identify patients with stage I FL. Adults patients 
with age 18 years and above with stage I FL as the first primary 
cancer diagnosed from 1992 to 2007 were included in the study. 
Patients who were microscopically confirmed and were included 
in research database were included in the study, while patients 
with unknown age, unknown year of diagnosis, incomplete 
demographic date, alive with no survival time, no data on radia-
tion therapy, death certificate only, and autopsy only cases were 
excluded from the study. Patients who received RT other than 
beam therapy (including radioactive implants, radioisotopes, 
combination of beam with implants or isotopes, unknown type 
method or source of radiation) were also excluded.
The study population was divided into various subgroups 
based on age (<60 and ≥60  years), sex, ethnicity [Caucasians 
(C), African-Americans (AAs), and Others (O)], and marital 
status [married (M), single (S), and separated/divorced/widowed 
(S/D/W)]. Binomial logistic regression was used to compute 
unadjusted and adjusted odds ratio (OR) to investigate on factors 
associated with receipt of RT, using SPSS version 20. SEER*Stat 
version 8.2.1 was used to compute 1- and 5-year relative survival 
(RS) for patients in no RT group and RT group, among various 
subgroups, and compared using Z score. Two-sided P-values 
were computed from the Z score for test of significance; P value 
<0.05 was considered to be statistically significant. RS is defined 
as the ratio of the observed survival of a group of cancer patients 
to survival of cancer free population in specified time period and 
specified place (10). Since the survival of cancer free popula-
tion is hard to estimate, the survival of the whole population is 
taken for the calculation with assumption that death of cancer 
patient is negligible compared to general population (11). The 
survival curves for RT and no RT groups were plotted using RS 
obtained with life table using SEER*Stat and actuarial method 
with 1-month intervals. Cansurv Software and Cox proportional 
hazard model were used to compare 5-year RS among RT and 
no RT group, after adjusting for age, sex, race, and marital status, 
and to compare factors associated with 5-year RS among patients 
receiving RT.
resUlTs
study Population
A total of 7315 patients, with Ann Arbor stage I, were included 
in the study (Figure  1). The median age at diagnosis was 
64 years with range of 18–98 years. Majority of the patients were 
Caucasians (91.1%), ≥60  years (59.2%), females (50.8%), and 
married (64.6%). Patients’ demographics are available in Table 1.
Among the patients with stage I FL, 36.5% patients received 
RT. The demographics of the patients with receipt of RT can be 
found in Table 1.
Factors associated with receipt of rT
Radiotherapy was omitted more often in elderly patients compared 
to younger patients (unadjusted OR of 0.64, P < 0.001; adjusted 
OR of 0.64, P < 0.001) and in AAs compared to Caucasian (unad-
justed OR of 0.64, P <  0.001; adjusted OR of 0.61, P <  0.001) 
patients. There was no significant difference in the receipt of RT 
for “Others” race compared to Caucasian (unadjusted OR of 1.24, 
P 0.06; adjusted OR of 1.19, P 0.14). There was no gender differ-
ence in the receipt of RT, when adjusted for other variables. When 
adjusted for other variables, there was no significant difference in 
receipt of RT for “Others” race compared to Caucasians (adjusted 
OR 1.19, P 0.14). The probability of receiving RT decreased with 
recent year of diagnosis (unadjusted and adjusted OR of 0.97 and 
0.98 for 1-year increase in year of diagnosis with P < 0.001 for 
both). The details of the factors associated with RT can be found 
in Table 2.
comparison of survival among Patients  
in rT and no rT group
Patients receiving RT had significantly better 1- and 5-year RS 
when compared to those who did not receive RT (1-year RS: 
99.9 ± 0.3 vs. 96.0 ± 0.4%, P < 0.0001, and 5-year RS: 97.3 ± 0.7 
vs. 88.4 ± 0.7%, P < 0.0001). When the RS obtained by life table 
and actuarial method with interval of 1 month was plotted for 
patients in RT and no RT group, the curves diverged early in 
the course and the difference increased with time. On subgroup 
analysis, 1-year survival was significantly better in RT group 
compared to no RT group for all cohorts except AAs, “Others” 
race, and younger patients (<60 years). There was no improve-
ment in 5-year survival for patients of “Others” race in RT group 
compared to no RT group.
Factors associated with survival:  
cox Ph Model
On Cox PH modeling, receipt of RT was independent predictor of 
better 5-year survival after adjusting for age, sex, race, and marital 
status (HR of 0.81 with P value of <0.0001).
Among patients receiving RT, female sex (HR of 0.088, 
P < 0.0001), older age (HR of 0.33, P < 0.0001), and Caucasian 
race (HR of 11.22 and 8.27 for AA vs. Caucasian and Others vs. 
Caucasian, respectively, with P <  0.0001) were associated with 
better 5-year survival compared to their counterparts, after 
adjusting for other covariates. Also, married patients had better 
survival compared to single or S/D/W (Table 3).
All patients with FL diagnosed from 
1992 to 2007 
N= 31305
Total number of patients with stage I FL
N = 9065 
Total number of stage I FL patients 
included in the study
N = 7315
Excluding
Patients with FL stages II to IV 
N=22240
Excluding
Age <18 years = 34
History of prior primary cancer = 1478
Receipt of RT other than beam radiation = 194
Unknown race = 44
Patients receiving RT
N = 2671
Patients not receiving RT
N = 4644
FigUre 1 | consolidated standards of reporting Trials (cOnsOrT) diagram.
TaBle 1 | Demographic distribution of patients receiving rT and not 
receiving rT.
characteristics all no 
radiotherapy 
(n = 4644)
radiotherapy 
(n = 2671)
P  
value*
Sex 0.039
Male 3600 (49.2%) 2243 (48.3%) 1357 (50.8%)
Female 3715 (50.8%) 2401 (51.7%) 1314 (49.2%)
Age <0.001
<60 years 2981 (40.8%) 1708 (36.8%) 1273 (47.7%)
≥60 years 4334 (59.2%) 2936 (63.2%) 1398 (52.3%)
Race
Caucasians 6662 (91.1%) 4218 (90.8%) 2444 (91.5%) <0.001
AA 308 (4.2%) 225 (4.8%) 83 (3.1%)
Others 345 (4.7%) 201 (4.3%) 144 (5.4%)
Marital status <0.001
Married 4722 (64.6%) 2893 (62.3%) 1829 (68.5%)
Single 776 (10.6%) 498 (10.7%) 278 (10.4%)
S/D/W 1481 (20.2%) 999 (21.5%) 482 (18.0%)
Unknown 336 (4.6%) 254 (5.5%) 82 (3.1%)
Total N = 7315 4644 (63.5%) 2671 (36.5%)
*P value by chi square.
AA, African-Americans; S/D/W, separated/divorced/widowed.
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DiscUssiOn
Current recommendations for treatment of stage I FL include 
watchful waiting, RT, and combined modality therapy (CMT). 
To the best of our knowledge, the recommendations are not based 
on prospective randomized controlled trials comparing different 
treatment modalities. A retrospective study by Advani et al. found 
survival for watchful waiting comparable to those who received 
immediate intervention, with 5-year overall survival for the 
whole population of 97% (12). There is a need for more research 
to identify factors or biomarkers that may help us identify indi-
viduals who may do well without therapy. Our study showed that 
less than half (36.5%) of the patients with stage I FL received RT 
and are consistent with the findings of other studies. In National 
LymphoCare Study, 56 out of 206 (27%) patients were treated 
with RT (13). A recent retrospective study utilizing National 
Cancer Data Base showed that only 21% patients with stage I FL 
received RT (7). It revealed that the use of RT was independently 
associated with improved overall survival (5- and 10-year OS 86 
and 68%, respectively, compared to 74 and 54% for those who 
did not receive RT, P < 0.0001). Although unclear, several fac-
tors, such as physician preference, large abdominal radiation field 
required, advanced age, concern for side effect, or patient refusal, 
may be responsible for the omission of RT as initial therapy.
The use of RT was found to be gradually but significantly 
declining with recent year of diagnosis. Similar to our findings, 
Vargo et  al. found gradual decrease in the utilization of RT in 
patients with early-stage FL with recent year of diagnosis. It 
decreased from 37% in 1999 to 24% in 2012 and corresponds with 
gradual rise in adoption of single agent chemotherapy or watchful 
waiting for management of these patients (7). Interestingly, a ret-
rospective study using SEER database by Shah et al. showed that 
the receipt of RT among patients with stage I diffuse large B cell 
TaBle 3 | Factors associated with survival among stage i Fl cases 
receiving rT.
Parameters estimate hazard ratio P value
Sex (female vs. male) 2.4323 0.0878 <0.0001
Age (≥60 vs. <60 years) 1.1073 0.3305 <0.0001
Race
Caucasians Reference
African-American −2.4173 11.2155 <0.0001
Others −2.1123 8.2672 <0.0001
Marital status
Married Reference
Single −0.5703 1.7688 <0.0001
S/D/W −0.1182 1.1254 <0.0001
Unknown −2.3245 10.2216 <0.0001
S/D/W, separated/divorced/widowed.
TaBle 2 | Factors associated with receipt of rT in patients with stage i follicular cancer.
Parameters Unadjusted Or 95% ci P value adjusted Or 95% ci P value
Age 0.639 0.580–0.704 <0.001 0.637 0.577–0.704 <0.001
Sex 0.905 0.822–0.995 0.039 0.958 0.867–1.058 0.394
Race
Caucasian Reference Reference
AA 0.637 0.493–0.823 0.001 0.606 0.467–0.785 <0.001
Others 1.236 0.993–1.540 0.058 1.179 0.944–1.473 0.146
Marital status
Married Reference Reference
Single 0.883 0.754–1.034 0.123 0.835 0.711–0.981 0.028
S/D/W 0.763 0.675–0.863 <0.001 0.858 0.753–0.977 0.021
Unknown 0.511 0.395–0.659 <0.001 0.526 0.406–0.681 <0.001
YOD 0.973 0.962–0.984 <0.001 0.975 0.964–0.986 <0.001
CI, confidence interval; age, ≥60 vs. <60 years; sex, female vs. male; AA, African-Americans; S/D/W, separated/divorced/widowed; YOD, year of diagnosis.
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lymphoma gradually declining with recent year of diagnosis (14). 
Reasons behind decline in the use of RT in lymphoma are not well 
studied, but advent of newer therapies, including immunotherapy 
and targeted therapy, may be contributing factors.
We identified demographic factors, such as AA race, singles 
and S/D/W martial status, and older age to be associated with 
decreased use of RT. Racial disparities in the receipt of definitive 
cancer therapy have been shown in multiple studies (15–18). In 
general, patients from racial or ethnic minorities, mostly AAs, are 
less likely to receive definitive cancer-directed therapy. Several 
factors, including lower socioeconomic status, lack of insurance 
coverage, perceptions and belief of patients, and bias of treating 
physician, have been attributed to ethnic disparities in cancer 
treatment (19). Older patients were less likely to receive RT 
compared to younger patients in our study. Older patients have 
poor performance status and higher number of comorbidities 
compared to younger patients (20, 21). Also, even though there 
has been a demonstration that elderly patients have the same 
incidence of side effects related to radiation therapy when the 
stage, performance status, and other clinical status are matched 
with that of younger patients, physicians are biased when they 
have to decide on RT in elderly patients (22–24). In one study, 
physician bias for the elderly patients resulted in significantly 
lower definitive therapy in elderly patients compared to younger 
patients with similar comorbidities (25). Lack of support system 
may contribute to lower utilization of RT among singles and 
S/D/W patients. Further research is warranted that is aimed at 
bridging disparities in treatment of these patients.
Our study showed superior survival rates for females. Study 
by Keegan et al. (26) showed better survival rates for females with 
lymphoma. Although unclear, other factors, such as differences in 
biology of lymphoma and differences in metabolism of chemo-
therapy, may be responsible for the differences in outcomes in 
these patients.
This study has innate limitations characteristic of population-
based registries. The details of the definitive treatment, including 
dose of radiation, number of cycles of treatment received, receipt 
of chemotherapy, and/or immunotherapy, such as rituximab, 
treatment complications, details of prognostic features, includ-
ing LDH level and performance status, reason for omission of 
a therapy either from physician or patient prospective, are not 
known. Strength of this study includes large population size, 
high-quality data, and long-term follow-up of patients.
cOnclUsiOn
Our study showed that approximately one-third of patients with 
stage I FL received RT. Elderly patients, AA race, and single or 
S/D/W as marital status were significant predictor of omission of 
RT in patients with stage I FL. Among patients receiving RT, old 
age, female sex, Caucasians, and married marital status predicted 
better 5-year RS.
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